20,003 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Purchased by Mubadala Investment Co PJSC

Mubadala Investment Co PJSC acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 20,003 shares of the specialty pharmaceutical company's stock, valued at approximately $2,463,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. IFP Advisors Inc acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth $25,000. Quadrant Capital Group LLC increased its holdings in shares of Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after buying an additional 101 shares during the last quarter. CoreFirst Bank & Trust acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth $28,000. Allianz SE acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth $29,000. Finally, Jones Financial Companies Lllp increased its holdings in shares of Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock worth $37,000 after buying an additional 130 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of research analyst reports. Barclays restated an "overweight" rating and set a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Royal Bank of Canada decreased their price target on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Robert W. Baird decreased their price target on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. HC Wainwright upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Finally, Morgan Stanley decreased their price target on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $182.79.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. This represents a 10.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Patricia Carr sold 4,813 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.42, for a total transaction of $695,093.46. Following the sale, the chief accounting officer now owns 8,237 shares in the company, valued at approximately $1,189,587.54. This trade represents a 36.88% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,236 shares of company stock valued at $3,956,190. Insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Up 2.7%

Shares of JAZZ stock traded up $2.91 during trading hours on Friday, hitting $108.98. 1,065,885 shares of the company were exchanged, compared to its average volume of 844,657. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a one year low of $95.49 and a one year high of $148.06. The business's 50-day simple moving average is $115.73 and its two-hundred day simple moving average is $121.95. The stock has a market capitalization of $6.72 billion, a price-to-earnings ratio of 15.35, a P/E/G ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The company had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. During the same period in the previous year, the business posted $2.68 EPS. The business's revenue for the quarter was down .5% on a year-over-year basis. Sell-side analysts predict that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.